Comparing Patient Satisfaction With Pataday or Bepreve
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare patient satisfaction with Pataday (Olopatadine
hydrochloride 0.2%) one daily (QD) and Bepreve (Bepotastine besilate ophthalmic solution
1.5%) two times a day (BID).